Model-informed precision dosing of infliximab to improve outcomes of individual patients with inflammatory bowel diseases KU Leuven
Background For over two decades, the 5 mg/kg weight-based dosing of infliximab was approved for inducing and maintaining remission in all patients with moderate-to-severe inflammatory bowel disease (IBD). Infliximab not only controls IBD symptoms but also modifies the disease course, enables long-lasting remission, and prevents long-term disability from structural damage. However, several issues with infliximab treatment still exist such as ...